| 摘要 |
<p>The invention provides a vaccine composition comprising the toxoplasma protein, SAG3 or an immunogenic derivative thereof in combination with a suitable adjuvant and/or carrier. The invention further provides a vaccine composition which additionally comprises the toxoplasma protein, SAG1 or an immunogenic derivative thereof, or a truncated SAG1 comprising amino acid residues 48-307 of SAG1.</p> |
